Table 3.

Treatment differences in changes from baseline in combined rTNSS and rTOSS, SAR, and PAR subgroups

		First week		Entire 2-week treatment
Parameter	Comparison	SAR	PAR	SAR	PAR
		N = 512	N = 652	N = 512	N = 652
		Treatment difference (95% CI), p value	Treatment difference (95% CI), p value	Treatment difference (95% CI), p value	Treatment difference (95% CI), p value
rTNSS	MP-AzeFlu vs. Aze*	− 1.93	− 1.64	− 2.11	− 1.93
		(− 2.72, − 1.15)	(− 2.33, − 0.95)	(− 2.87, − 1.36)	(− 2.60, − 1.27)
		< 0.0001	< 0.0001	< 0.0001	< 0.0001
	MP-AzeFlu vs. Flu**	− 1.16	− 1.28	− 0.88	− 1.17
		(− 1.95, − 0.37)	(− 1.97, − 0.60)	(− 1.64, − 0.12)	(− 1.82, − 0.51)
		0.0043	0.0003	0.023	0.0006
rTOSS	MP-AzeFlu vs. Aze*	− 0.63	− 0.59	− 0.67	− 0.59
		(− 1.16, − 0.11)	(− 1.04, − 0.14)	(− 1.18, − 0.16)	(− 1.02, − 0.16)
		0.0177	0.0108	0.0101	0.0076
	MP-AzeFlu vs. Flu**	− 0.89	− 0.78	− 0.75	− 0.67
		(− 1.42, − 0.36)	(− 1.23, − 0.33)	(− 1.26, − 0.23)	(− 1.10, − 0.24)
		0.001	0.0007	0.0044	0.0021

Least square means, (95% confidence intervals for pairwise differences), and p value (bold indicates statistical significance)